Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT03305536

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03305536
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Lebanon (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03305536. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2020-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)
Acronym
DECAV-K2
Condition
Aortic Valve Disease
Intervention (Dietary supplement)
Vitamin K2 (Menaquinone 7) + Vitamin D3
Lead sponsor
Hopital St. Georges, Ajaltoun (class: other)
Collaborator
Omicron Pharmaceuticals (class: industry)
Collaborator
Nattopharma ASA (class: industry)

Record details

Record id
cardio:ct-nct03305536
Content hash
9c1eee7c46ad5c1dcaca113f97848ba5716f7dfdd2ec1e611bea0751a1eaaf9f